Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer

Background Epithelial growth factor receptor inhibitors (EGFRi) and bevacizumab are the two main target therapies available for first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC). However, the optimal sequencing of these agents remains unclear. In this study, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Martins, Diana, Rodrigues, Jéssica, Redondo, Patrícia, Julião, Ivo, Faustino, Cátia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042308/
https://www.ncbi.nlm.nih.gov/pubmed/35494924
http://dx.doi.org/10.7759/cureus.23543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042308/
https://www.ncbi.nlm.nih.gov/pubmed/35494924
http://dx.doi.org/10.7759/cureus.23543

Ejemplares similares